Rivaroxaban to prevent clinical outcomes in covid 19 patients: MICHELLE TRIAL MD Editorial Team19 Feb 2022 9:00 AM ISTCovid-19 also known SARS Cov-2 is popularly known to cause more fatal events where severe respiratory problems and multi organ failure in the infected...
DOACS Effectively Reduces VTE Recurrence in Cancer Patients MD Bureau15 Feb 2022 9:00 AM ISTDirect oral anticoagulants (DOACs) are now considered the standard of care for the treatment of venous thromboembolism (VTE) in noncancer patients for...
In AF, rivaroxaban tied with an increased risk of major ischemic or hemorrhagic events: Study Dr. Shravani Dali28 Jan 2022 9:00 AM ISTAnticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more is associated with more risk for major ischemic and...
Apixaban a better anticoagulant compared to Rivaroxaban in AF, finds JAMA study MD Editorial Team6 Jan 2022 9:00 AM ISTAtrial fibrillation incidence has increased the aging of populations worldwide, and increased survival with chronic diseases, the incidence and...
Apixaban bests rivaroxaban in lowering rates of recurrent VTE and bleeding: Study MD Editorial Team11 Dec 2021 10:00 AM ISTGhadeer K. Dawwas and colleagues have found in a new study that patients with venous thromboembolism (VTE) who were new users of apixaban had...
Combination of Rivaroxaban And Aspirin Improves CV Outcomes: COMPASS Trial Dr. Nandita Mohan4 Dec 2021 5:49 PM ISTCardiovascular diseases are the leading cause of death globally. Though new medications and the use of effective secondary prevention strategies, 5%...
Rivaroxaban and aspirin combo improves CV outcomes in stable ASCVD: COMPASS Trial MD Editorial Team4 Dec 2021 1:50 PM ISTCardiovascular diseases are the leading cause of death globally. Though new medications and the use of effective secondary prevention strategies, 5%...
Rivaroxaban Enhances Endothelial Function in Patients with Type 2 Diabetes: Study MD Bureau12 Nov 2021 9:00 AM ISTPatients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future...
Rivaroxaban & aspirin benefit PAD patients undergoing lower extremity revascularization: study Dr. Shravani Dali29 Oct 2021 9:45 AM ISTPatients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) benefit from low-dose rivaroxaban and aspirin ...
Aspirin with DOACs: More risk with same reward, says JAMA study Dr. Kamal Kant Kohli20 April 2021 7:06 AM ISTResearchers have found in an observational study that concomitant use of a direct oral anticoagulant (DOAC) plus aspirin in some cardiovascular...
Rivaroxaban and Aspirin combo reduces vascular risk in Lower Extremity PAD: JAMA Dr. Nandita Mohan20 Jan 2021 6:00 PM ISTResearchers have recently observed that treatment with rivaroxaban and aspirin in combination compared with aspirin alone led to a large absolute...
NATCO launches anticoagulant drug Rivaroxaban in India Ruchika Sharma18 Dec 2020 12:00 PM ISTHyderabad: Natco Pharma Limited has recently announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant...
